论文部分内容阅读
目前晚期非小细胞肺癌患者的治疗效果还不理想,一线化疗的有效率为20%~40%,中位生存期为8~10个月,现有的化疗方案已达到“化疗疗效的平台”。一系列靶向治疗药物的出现,将非小细胞肺癌的治疗引向分子水平。然而,目前用于治疗非小细胞肺癌的酪氨酸激酶抑制剂的疗效维持时间尚无法令人满意,中位疾病进展时间为6~8个月。对于复发和进展的非小细胞肺癌,在三线治疗之后,多采用以最佳支持疗法为主的治疗方案。索拉非尼是一种多靶点的酪氨酸激酶抑制剂,能够同时作用于肿瘤细胞的多个分子靶点,产生多种药理活性,且患者的依从性也更好,目前已被应用于肾癌、肝癌、胃肠间质瘤、乳腺癌和慢性粒细胞白血病的治疗,开创了靶向治疗的新时代。本文综述了多靶点酪氨酸激酶抑制剂索拉非尼治疗非小细胞肺癌的临床研究进展。
At present, the treatment effect of patients with advanced non-small cell lung cancer is still not satisfactory. The effective rate of first-line chemotherapy is 20% -40% and the median survival time is 8-10 months. The existing chemotherapy regimen has reached the platform of “chemotherapy efficacy ”. The advent of a series of targeted therapies led to the treatment of non-small cell lung cancer at the molecular level. However, the current efficacy of tyrosine kinase inhibitors for the treatment of non-small cell lung cancer remains unsatisfactory and the median time to disease progression is 6 to 8 months. For recurrent and advanced non-small cell lung cancer, after the third-line treatment, the use of the best supportive therapy-based treatment. Sorafenib is a multi-targeted tyrosine kinase inhibitor that is capable of simultaneously acting on multiple molecular targets in tumor cells, generating multiple pharmacological activities and being more patient-friendly and has now been used In the treatment of kidney cancer, liver cancer, gastrointestinal stromal tumors, breast cancer and chronic myeloid leukemia, a new era of targeted therapy has been established. This review summarizes the clinical research progress of sorafenib, a multi-target tyrosine kinase inhibitor, for the treatment of non-small cell lung cancer.